Tandem Diabetes Care (TNDM) Price to Sales (2013 - 2026)

Tandem Diabetes Care (TNDM) has reported Price to Sales for 14 consecutive years, with 4.12 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Sales fell 21.18% year-over-year to 4.12; the trailing twelve-month figure through Jun 2026 stood at 1.01 (down 19.81% YoY), and the FY2025 full-year result was 1.48, down 41.73% from the prior year.
• Price to Sales declined to 4.12 in Q2 2026 per TNDM's latest filing, from 5.31 in the prior quarter.
• Across five years, Price to Sales topped out at 42.27 in Q1 2022 and bottomed at 3.3 in Q3 2025.
• Historically, Price to Sales has averaged 11.25 across 5 years, with a median of 9.15 in 2023.
• The sharpest annual moves came in 2022 and 2024: Price to Sales plunged 71.26% in 2022, then jumped 56.44% in 2024.
• Over 5 years, Price to Sales stood at 13.15 in 2022, then decreased by 25.08% to 9.85 in 2023, then dropped by 14.29% to 8.44 in 2024, then sank by 38.79% to 5.17 in 2025, then retreated by 20.25% to 4.12 in 2026.
• According to Business Quant data, Price to Sales over the past three periods registered 4.12, 5.31, and 5.17 for Q2 2026, Q1 2026, and Q4 2025 respectively.